Taxpayers overpaid for Mylan's EpiPen by $1 billion says Senator Chuck Grassley.
American taxpayers may have been overcharged by as much as $1.27 billion over a decade for the anti-allergy device EpiPen, a U.S. senator said Wednesday.
That amount is far more than the $465 million that EpiPen's owner, the big drugmaker Mylan, said that it agreed to pay the federal government last year to settle claims that it overcharged the nation's Medicaid system for the devices.
